37 results about "Vitamin binding" patented technology

The invention provides a subspace fusion-based protein-vitamin binding location point predicting method. The method comprises the steps of feature extracting and feature combining: extracting evolution information, secondary-level structural information the binding tendency information of a protein by respectively using a PSI-BLAST, a PSIPRED and a protein-vitamin binding location point tendency table, and converting amino acid residues in a protein sequence into a vector presentation mode by a sliding window and serial combination; using a multi-feature selection algorithm to perform feature selection on an original feature space for multiple times; forming a feature subspace by feature subsets obtained from feature selection every time and establishing multiple feature subspaces; training one SVM (support vector machine) classifier for each obtained feature subspace; fusing multiple SVM classifiers which are trained by a weighted average classifier fusing mode; performing protein-vitamin binding location prediction on the protein to be predicted based on a fused SVM predictor. The prediction method is fast in prediction sped and high in prediction precision.

The present invention relates to a method for diagnosing a subject's Alzheimer's disease state. The method involves providing a database containing information relating to protein expression levels associated and not associated with Alzheimer's disease. The database includes information relating to at least a majority of the following proteins: albumin, alpha-1-antitrypsin, apolipoprotin E, apolipoprotein J, complement component 3, contactin, fibrin beta, Ig heavy chain, Ig light chain, neuronal pentraxin receptor, plasminogen, proSAAS, retinol-binding protein, transthyretin, and vitamin D binding protein. Information relating to proteins found in one or more cerebrospinal fluid samples from a subject is also provided and a database is used to analyze the information from the subject to diagnose the subject's Alzheimer's disease state. Also disclosed is a computer readable medium and a system, both useful in carrying out the present invention.

Compositions containing a therapeutic peptide covalently linked to Vitamin B12 at the 5′-hydroxyl group of the ribose moiety of α-ligand are described. The length of the linkage is optimized so that the biological activity of both the Vitamin B12 and the therapeutic peptide is maintained. Therapeutic peptides for conjugation with vitamin B12 include insulin, PYY, NPY and GLP-1. Attachment to Vitamin B12 provides uptake of the therapeutic peptide from the digestive tract and longer residence time.

Agents for promoting bone deposition and growth in a mammalian subject. The agents are O-glycosylated and non-glycosylated peptides that are derived from vitamin D binding protein, collectively referred to hereinafter as “DBP” peptides. The DBP peptides are from 3 to 18, preferably from 4 to 14 amino acids in length and comprise a sequence which is at least 80% identical, preferably at least 90% identical to the amino acid sequence of a fragment contained within domain III of DBP. Methods for promoting bone deposition in a subject in need of the same are also provided. The methods comprise administering to the subject a therapeutically effective quantity of an agent selected from the group consisting of an activated form of vitamin D binding protein referred to hereinafter as “ADBP”, one or more DBP peptides, and combinations thereof. The agents may be administered locally or systemically.

The invention discloses application of vitamin D binding protein as a marker in diagnosis of mental disease depression, and particularly relates to application of a reagent for detecting the content of the vitamin D binding protein in preparation of a reagent for diagnosing the mental disease depression. Differential expression of the vitamin D binding protein in plasma of schizophrenia, bipolar mania, depression and non-mental disease control persons is indicated, and the specificity of the vitamin D binding protein in plasma of depression patients is only improved; the protein is singly usedas a peripheral blood biomarker to detect the content of the protein and is used for diagnosing depression, so that the differential diagnosis accuracy of depression and healthy people or schizophrenia and bipolar mania of other mental diseases can be remarkably improved. Therefore, vitamin D binding protein content detection has high clinical application value in depression diagnosis, and a brand-new way is provided for rapid and effective diagnosis of mental disease depression.

The present invention is directed to compositions and devices for transdermally administering vitamin B12 to a subject. In one aspect, a vitamin B12 containing composition suitable for transdermal administration is provided in the form of a shelf stable transdermal delivery patch. Such patches contain vitamin B12 combined with selected penetration enhancers and vitamin B12 stabilizers.

The present invention provides a cosmetic patch which can contain therein either one of a water soluble vitamin and a fat soluble vitamin, particularly when the vitamin is vitamin C, can contain and retain vitamin C stably while avoiding its deterioration due to oxidation or hydrolysis and not causing deterioration of the gel, and is equipped with a desired level of adhesive force; a using method of a cosmetic patch capable of effectively transferring vitamin C into the skin from the cosmetic patch; and a cosmetic patch package for storing the cosmetic patch therein. The present invention relates to a cosmetic patch obtained.by incorporating a vitamin in an adhesive polyurethane gel which has hydrophilic alkylene oxide segments and hydrophobic alkylene oxide segments and has most or all of these segments in liquid form at normal temperature.

It has been demonstrated that one of Vitamin D Binding Protein (DBP) biological functions is to enhance the chemotactic activity of C5a and C5a des Arg. The present invention has found that peptides having sequences that substantially correspond to a specific region in the N-terminal domain I of DBP can block the DBP enhancement of C5a or C5a des Arg chemotactic activity. Based in this discovery the present invention provides DBP antagonist peptides and the use thereof for the treatment C5a or C5a des Arg-mediated disorders.

The invention relates to a detection method of vitamin B12 and a sample pretreatment method of vitamin B12, and belongs to the technical field of detection of biological samples. The pretreatment method comprises the following steps of obtaining a to-be-detected sample solution, and adding a protein releasing agent and a complexing agent, wherein the protein releasing agent is used for releasing the vitamin B12 of a to-be-detected sample from binding protein; the complexing agent is a complex with cyanide ions, and the total stability constant beta of the complex in a water solution is 1010 to 1045; dissociating the cyanide ions from the complex in the solution, binding the cyanide ions and the released vitamin B12, and forming stable cyanocobalamine for measuring. The detection method and sample pretreatment method have the advantages that the hypertoxic cyanide is replaced with the low-toxic complex with the cyanide ions, the dissociated trace cyanide ions can react with the vitamin B12 in the to-be-detected sample, and the stable cyanocobalamine is produced; the requirement of sample treatment is met, the sample can be fully treated, and the larger toxicity is not produced.

Methods for preparing a sample for detection of an analyte of interest that is bound in vivo to a protein are provided. The method comprises providing a processing reagent comprising metaperiodate and contacting a sample suspected of comprising an analyte of interest associated with a protein with the processing reagent to form a mixture. The analyte of interest, if present in the sample (or mixture), is separated from its associated protein for detection of the analyte of interest. In one embodiment, the method is applied to samples for the detection of levels of vitamin D circulating in the blood. Samples are processed using the reagent disclosed herein to separate the analyte of interest, vitamin D or a metabolite thereof, from the vitamin D binding protein and / or albumin, for detection of the analyte separated from its binding protein(s).

The vitamin D binding protein (Gc protein) and its small region (approximately 1 / 5 of the Gc peptide, known as region III) were cloned with the aid of baculovirus vectors. The cloned Gc protein and cloned domain (Cd) peptide were treated with immobilized β-galactosidase and sialidase to produce macrophage activating factors GcMAFc and CdMAF, respectively. These cloned macrophage activating factors and GcMAFs can be used to treat cancer, HIV infection, and osteoporosis, as well as as adjuvants for immunization and vaccination. Methods and antibody-sandwich ELISA kits for detecting serum or plasma α-N-acetylgalactosaminidase activity in patients with cancer and HIV infection were developed.

The invention relates to a blank biological sample preparation method, which specifically comprises: (1) separating vitamins bound to proteins under an acid / alkali condition to release endogenous vitamins; (2) adsorbing the released vitamins with an adsorption material; and (3) separating the adsorption material from a biological sample through high-speed centrifugation to obtain a vitamin-free blank biological sample. According to the present invention, the preparation process can effectively remove the endogenous vitamin compounds in the biological sample, can retain the characteristics of the biological sample to the greatest extent, and can provide the matrix environment similar to the to-be-detected biological sample for the clinical quantitative detection of vitamin compounds.

The present invention provides biological markers associated with gastric cancer. In particular, the present invention provides a method of diagnosing gastric cancer (GC) in a subject, the method including: measuring an expression level of one or more proteins in the subject, wherein the one or more proteins are selected from the group consisting of vitamin D binding protein (VDBP), clusterin, insulin like growth factor binding protein complex acid labile subunit (IGFALS), and afamin; comparing the expression level of the or each protein in the subject to a reference expression level for the or each protein; and diagnosing GC in the subject on the basis of the comparison. On the basis of the identification of biological markers associated with gastric cancer, the present invention also provides a method of determining if a subject is susceptible to developing gastric cancer, a method of assessing progression of gastric cancer in a subject, a method for screening a candidate therapeutic agent useful for treating gastric cancer in a subject, and a kit for diagnosing gastric cancer in a subject.

A reagent composition for releasing vitamin D compounds bound to vitamin D-binding protein, an in vitro method for the detection of a vitamin D compound in which the vitamin D compound is released from vitamin D-binding protein by the use of this reagent composition and the reagent mixture obtained in this manner. The use of the disclosed reagent composition to release vitamin D compounds as well as a kit for detecting a vitamin D compound which contains the reagent composition for releasing vitamin D compounds in addition to common detecting reagents.

The invention discloses a dissociation method of 25-hydroxyvitamin D binding protein. The dissociation method comprises the following steps: preparing a mother solution, taking a serum sample, addingthe mother solution, carrying out vortex mixing for 1min, uniformly mixing the obtained solution, allowing the obtained mixed solution to stand for 5min, and centrifuging the mixed solution in a centrifuge; and taking the obtained supernatant of the solution, adding ethanol, carrying out vortex mixing, allowing the obtained mixed solution to stand, placing the obtained solution in the centrifuge,centrifuging the solution, taking the obtained supernatant, placing the supernatant in a new centrifuge tube, blow-drying the supernatant by using a nitrogen blow-drying instrument, adding a separation mobile phase, re-dissolving the dried supernatant, uniformly mixing the re-dissolved supernatant and the separation mobile phase, and carrying out LC-MS / MS detection. The solution uses dithiothreitol with a certain concentration, so the 25-hydroxyvitamin D to be analyzed can be well separated, the detection result of the 25-hydroxyvitamin D can be improved, and the overall content of the vitaminD is further determined; and the dithiothreitol has strong reducibility, so the stability of the 25-hydroxyvitamin D in the purification and extraction process is improved.

The present invention relates to beta-lactoglobulin-vitamin conjugate comprising sugar alcohols. The conjugate comprises beta-lactoglobulin, VE, sorbitol and maltitol which are subjected to high-pressure pulse glycosylation treatment. The high-pressure pulse glycosylation treatment means that a phosphate buffer solution with a concentration of 0.01 mol / L and a pH value of 7.4 is treated in a high-voltage electric field for 80 microseconds so as to obtain the beta-lactoglobulin with a concentration of 1 mg / mL. The electric field intensity of the high-voltage electric field is 30 kV / cm, and theelectric field waveform is unipolar square wave. The invention also discloses a preparation method of the beta-lactoglobulin-vitamin conjugate comprising the sugar alcohols. According to the invention, the beta-lactoglobulin is modified after the high-pressure pulse glycosylation treatment, so that the secondary structure and the tertiary structure of the beta-lactoglobulin are forced to be changed, the allergenicity of protein is effectively reduced, and meanwhile, natural emulsifiers of the sugar alcohols are added to improve the combination binding rate.

This invention relates to the targeted delivery of cytotoxic drugs A) to lymphocytes responsible for the rejection of transplanted tissues, such as kidneys or hearts or bone marrow cells; B) the use of a non-toxic naturally existing delivery system to transport high concentrations of radiosensitizers to cancer cells; and C) to the targeted delivery of drugs in medical diagnosis and treatment of cancer.

Vitamin B12 can be conjugated to anti-cancer drugs to deliver these drugs selectively to tumors, wherein the conjugates bind to transcobalamin. The complex of vitamin B12 and transcobalamin is recognized and taken into cells by specific cell surface receptors which are overexpressed in rapidly dividing cells.

The invention discloses a preparation method of a nano-diamond beauty makeup product, and belongs to the field of diamond application. The preparation method comprises the following four parts: strong acid treatment of the nano-diamond, N2 atmosphere vacuum heat treatment, surface functionalization treatment of the nano-diamond, and combination of the nano-diamond and vitamin C. The method is simple to operate, the product has the properties of low toxicity, biocompatibility, chemical inertness, fluorescence effect and the like, and the nano-diamond can be combined with the skin surface, so that the transdermal moisture loss is reduced, the function of the water lipid skin surface is influenced, and the skin is protected from aging.

The invention discloses a preparation method of a stable vitamin A preparation. The preparation method includes following steps: (1) activating attapulgite and performing high-temperature treatment to the attapulgite; and (2) adding the treated attapulgite in a vitamin A ethanol solution for adsorption. In the invention, the attapulgite is treated through acid and then treated at a high temperature to form activated attapulgite, and then the activated attapulgite is combined with vitamin A. The preparation is good in stability. The fat-soluble vitamin which is difficult to disperse is prepared into solid powder, so that the defect of vitamin A is overcome. The vitamin A preparation is convenient to use and is an excellent raw material for producing feeds without technical limit.

The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and(ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; and (iii) vitamin C and / or selenium, optionally in combination with vitamin E, in the manufacture of a product for therapeutically preventing and / or slowing down brain atrophy in a human subject in need thereof.

The invention discloses a synthesis method and application of an miRNA-carrying VB12 binding type nano-composite. The synthesis method comprises the following steps: mixing and dissolving a PLGA-PEG nano-composite, vitamin B12, EDC and DMAP in an anhydrous solvent A, and performing stirring for reaction at 15-40 DEG C; and after the reaction is finished, performing dialyzing, and removing the solvent to obtain the vitamin B12 combined nano-composite. The synthesis method has the advantages of mild preparation conditions, cheap required raw materials, convenient operation, simple process, highefficiency and practicability. The prepared nano-composite optimizes nucleic acid drugs from three aspects of water solubility, stability and tumor targeting, endows the nucleic acid drugs with efficient and low-toxicity anti-tumor effects, and has a wide application prospect in the field of tumor treatment.

The invention discloses the application of vitamin D binding protein as a marker in the diagnosis of mental disease depression, and specifically refers to the application of a reagent for detecting the content of vitamin D binding protein in the preparation of reagents for diagnosing mental disease depression. The present invention shows that vitamin D-binding protein is differentially expressed in the plasma of schizophrenia, bipolar mania, depression and non-mental disease control subjects, and only specifically increases in the plasma of patients with depression; by using the protein alone as Detection of peripheral blood biomarkers for the diagnosis of depression can significantly improve the accuracy of differential diagnosis between depression and healthy people or other mental diseases such as schizophrenia and bipolar mania. Therefore, the detection of vitamin D binding protein content has high clinical application value in the diagnosis of depression, and provides a new way for the rapid and effective diagnosis of depression in mental diseases.

A buffer solution includes methanol and the at least one fluoroalkyl surfactant selected from perfluorocarboxylic acids, perfluorosulfonic acids and their salts. A method for detecting and quantifying, in vitro, vitamin D and / or at least one vitamin D metabolite in a biological sample includes treating the sample by incorporating at least one fluoroalkyl surfactant and methanol so as to dissociate the vitamin D and / or its metabolite(s) to be detected from vitamin D binding protein; and detecting and quantifying vitamin D and / or at least one of its metabolites, in particular by immunoassay. A kit for detecting and quantifying vitamin D and / or at least one vitamin D metabolite by immunoassay and including the solution is provided.

The invention relates to a urine protein marker for asthma and application thereof. The present application relates to the application of a urine protein marker selected from a group consisting of epidermal growth factor receptor substrate 15, Cathelicidin antimicrobial peptide, haptoglobin, alpha-1-acidic glycoprotein 1, prolactin-inducing protein homolog, odorant binding protein 2a, protein LEG1homolog, complement factor B, retinoid beta, beta-2 microglobulin, prothrombin, eosinophilic granulocyte cationic protein 1, protein AMBP, plasminogen, a procollagen C-endopeptidase enhancer 1, a sodium channel and gridding protein connecting agent 1 and vitamin D binding protein. According to the application, an animal model for screening the asthma-related urine protein marker is established, the asthma-related urine protein marker is obtained by using the established animal model, and an application of a detection reagent of the marker in preparation of a kit for diagnosing asthma of a subject is also established.

The invention provides a diabetic kidney disease early warning model established by synchronously detecting urine markers based on a urine suspension array, and a diabetic kidney disease prediction model established by four urine biomarkers including vitamin D binding protein, human tumor necrosis factor receptor 2, retinol binding protein 4 and kidney injury molecule 1, Y = 0.14 * VDBP + TNFR2 + 0.01 * RBP4 + 15.47 * KIM-1-19.24. According to the diabetic kidney disease early-warning model established based on synchronous detection of the urine markers, a new diagnosis means is provided for early warning of DKD, and the diabetic kidney disease early-warning model has certain potential clinical value in delaying development of DKD and assisting treatment of DKD. Clinical tests prove that synchronous combined detection of VDBP, TNFR2, RBP4 and KIM-1 in 11 urine biological markers has high specificity and sensitivity for early diagnosis of DKD, the diagnosis value of the kit is superior to that of any other single index, and the kit has the application prospect of being developed into a chip for early diagnosis of DKD.

The present invention relates to a composition for treating and preventing degenerative brain diseases comprising a complex of vitamin C and an aptamer binding to the vitamin C as an active ingredient, and the composition of the present invention has improved and therapeutic effects in a Parkinson's disease experimental model and so the composition of the present invention can be used as medicines and health functional foods for patients with degenerative brain diseases including Parkinson's disease.

Method of diagnosis and prognosis of contrast media induced nephropathy (CIN) comprising the steps of i) taking a urine sample from a patient exposed to the application of contrast media, notably patients subjected to coronary angiography; ii) assessing the level of vitamin D binding protein (VDBP) in the urine sample obtained in step (i); iii) relating the urinary vitamin D binding protein level determined in step (ii) to a pre-selected threshold level, wherein a urinary vitamin D binding level higher than said pre-selected threshold level indicates that the patient is at risk of renal failure and in need of a dialysis treatment.

The present invention relates to a composition for alleviating and treating hair loss, hair damage, and a skin disease of an animal, comprising vitamin C and an aptamer binding to vitamin C as active ingredients, and, as alleviation and treatment effects were present in all subjects with hair loss, hair damage, atopic dermatitis, eczema, and contact dermatitis, when treated with the composition of the present invention, the composition can be used as a drug, cosmetic product, etc. for subjects with the conditions.